Holen Sie sich die Stockscreener-App
200.53
0.37%
0.8199
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$199.71
Offen:
$198.88
24-Stunden-Volumen:
349.00K
Relative Volume:
0.30
Marktkapitalisierung:
$29.60B
Einnahmen:
$9.60B
Nettoeinkommen (Verlust:
$1.37B
KGV:
21.52
EPS:
9.3182
Netto-Cashflow:
$2.32B
1W Leistung:
+2.47%
1M Leistung:
+3.45%
6M Leistung:
+14.66%
1J Leistung:
+60.67%
1-Tages-Spanne:
$198.41
$201.22
1-Wochen-Bereich:
$193.19
$201.75
52-Wochen-Spanne:
$121.05
$205.97
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
200.50 | 29.02B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,110.58 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
237.62 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
233.99 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
118.76 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.84 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
WilmerHale Advises Biogen in Acquisition of RayThera - WilmerHale
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.
Cantor Fitzgerald maintains Biogen stock rating on BIIB080 outlook - Investing.com
Biogen to acquire RayThera for USD 1B - Medical Buyer
Biogen Inc. (BIIB) Investor Outlook: Evaluating the Potential 12% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biogen Inc. (BIIB) And Encourages Shareholders to Reach Out - ACCESS Newswire
Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs - MSN
Denali to Sell Priority Review Voucher for $195M Cash Boost - TradingView
Biogen acquires RayThera in deal worth up to $1 billion - qz.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Biogen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Biogen Stock$1 billion RayThera deal to expand immunology pipeline - AD HOC NEWS
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera - BioPharma Dive
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline - Benzinga
Biogen Enters $1 Billion Agreement to Acquire RayThera Inc. - Pharmaceutical Executive
Biogen snags San Diego biotech for $1B as immunology expansion continues - The Business Journals
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout - Yahoo Finance
Biogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says - marketscreener.com
Biogen Agrees to Acquire RayThera for Up to $1B - Contract Pharma
Needham reiterates Buy on Biogen stock after RayThera acquisition - Investing.com
Needham reiterates Buy on Biogen stock after RayThera acquisition By Investing.com - Investing.com Canada
Biogen makes up to $1B immuno play with RayThera takeover - BioSpace
Biogen (BIIB) Expands Immunology Portfolio with $1B RayThera Acquisition - Blockonomi
Biogen to Acquire RayThera in Up to $1 Billion Deal to Expand Immunology Pipeline - marketscreener.com
Morgan Stanley Raises Price Target on Biogen to $224 From $206, Keeps Equalweight Rating - marketscreener.com
Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion - GuruFocus
Biogen to Acquire Biotechnology Firm RayThera for Up to $1 Billion - marketscreener.com
Biogen Inc (BIIB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biogen to Acquire RayThera for Up to $1 Billion - GuruFocus
Biogen (BIIB) to Acquire RayThera for Up to $1 Billion - GuruFocus
Biogen targets immunology growth with $1 billion RayThera deal - Reuters
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Biogen to acquire RayThera for up to $1B, boosting immunology pipeline with new drug candidates. - Pluang
Biogen to acquire RayThera for up to $1 billion By Investing.com - Investing.com Canada
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. - Biogen
Biogen to acquire RayThera for $1 billion - marketscreener.com
Biogen Expands Immunology Pipeline With Agreement To Acquire Raythera Inc. - TradingView
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Expands Immunology Pipeline with $1 Billion RayThera Acquisition to Advance Next-Generation Therapies - bio-itworld.com
Biogen Inc. entered into a definitive agreement to acquire RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others for $1 billion. - marketscreener.com
Biogen to Report Second Quarter 2026 Financial Results July 29, 2026 - Biogen
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Biogen (BIIB) Stock After Breakthrough SMA And Lupus Updates Is A 9.4% Undervaluation Story - simplywall.st
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
2026-06-15 | Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:BIIB | Press Release - Stockhouse
Mizuho Trims Price Target on Biogen to $221 From $236, Keeps Outperform Rating - marketscreener.com
Biogen Inc. (BIIB) Stock Analysis: Navigating a 10% Upside Potential with Strategic Collaborations - DirectorsTalk Interviews
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Keeney Adam | Head of Corporate Development |
May 01 '26 |
Option Exercise |
0.00 |
939 |
0 |
6,820 |
| Godbout Sean | Chief Accounting Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
181 |
0 |
1,396 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 12 '26 |
Buy |
195.03 |
3 |
585 |
19,611 |
| Viehbacher Christopher | President and CEO |
Feb 06 '26 |
Option Exercise |
0.00 |
24,461 |
0 |
36,548 |
| Singhal Priya | Head of Development |
Feb 06 '26 |
Option Exercise |
0.00 |
6,900 |
0 |
12,115 |
| Singhal Priya | Head of Development |
Feb 09 '26 |
Sale |
199.83 |
2,660 |
531,548 |
8,043 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 06 '26 |
Option Exercise |
0.00 |
8,725 |
0 |
21,016 |
| Kramer Robin | Chief Financial Officer |
Feb 06 '26 |
Option Exercise |
0.00 |
5,003 |
0 |
12,535 |
| Keeney Adam | Head of Corporate Development |
Feb 06 '26 |
Option Exercise |
0.00 |
5,080 |
0 |
6,875 |
| Izzar Rachid | Head of Global Product Strat. |
Feb 06 '26 |
Option Exercise |
0.00 |
6,889 |
0 |
11,786 |
0.76%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):